cposch

Why ARIAD Pharmaceuticals Needs an SEC Investigation

I 100% agree with this article.

As a long, I recommend every single long of Ariad to file a report with the SEC to investigate Berger and Ariad. This company has been run, wrongly, by this guy for way too long. If he won't resign on his own, perhaps shareholders need another avenue - and the SEC hopefully will be just that.

Why ARIAD Pharmaceuticals Needs an SEC Investigation

Look at the history of this company since the IPO.

Look at the performance of the company since the IPO (excluding the hype and bubble of 2000 which was a complete hoax).

Look at the abysmal failures of products since the IPO.

Look at all the personnel and Directors who have resigned since the IPO.

Look at the AGTI agreement in the first place. How many CEOs of public companies design a scheme whereby the CEO is allowed to be rewarded financially in a private subsidiary, by products funded by the public company and financed by public investors?

Look at Harvey Berger's compensation arrangement since the IPO. Last year his total package was roughly $1 million - (which the company bleeds 10's of millions of dollars a year, with no commercial product, and many empty promises).

This company is nothing but a money machine for Dr. Berger and a couple others. Everyone else is funding their lives.

As a shareholder in this company, I strongly advise the author of this article and others, to contact the SEC at the email address provided, and also contact the largest percentage holders in Ariad to voice their opinion to author a proxy to kick Dr. Berger out of his position.

This company, in my opinion, will always be a failure as long as Dr. Berger is running it. Look at history, and what he has brought to shareholders - nothing but losses. Not for him, however....I'm sure he's made millions off public investors.

Reversal of Stem Cell Research Ban: 13 Stocks to Benefit

Will someone tell this author to do his homework and stop pumping Ariad Pharma. This stock is not a stem-cell stock, but merely a company with a history of massive losses from a CEO who was runner up for "Worst Biotech CEO of 2008."

Ariad's 'Patent' Is Finally, Officially Dead

This whole episode was just another example of the gross negligence and corruption from the CEO of this company. He has turned a public company into his own private wealth creator for himself.....with shareholders and secondaries paying his $500,000 and free options since the IPO, while giving shareholders nothing but a few hundred million in losses and no product....

12 Stem Cell Stocks - Updated

Best rif-raf to get rid of would be Harvey Berger over at Ariad. Worst Biotech CEO going.

12 Stem Cell Stocks - Updated

How is Ariad (ARIA) a stem-cell stock?

Sounds to me like a pump-job trying to get the shares to artificially inflate on a pump and dumper.

Who Is the Worst Biotech CEO?

Please do tell us why Berger was your Worst Biotech CEO of 2008 nominee. I agree, and I am long the stock.

This guy needs to GO.

Biotech: The Next Big Bubble?

This moron is saying Aschoff is great?

Aschoff recommended CEGE and KERX and said they would be approved.

CEGE is at .20 cents. KERX is at .15 cents. Both were trading at roughly $5 when he put those recommendations out.

Dendreon Gets Another Analyst Thumbs-Down

What Mike Huckman didn't report is this: that Joe Pantginis left (or was fired? - more on that later) Cannacord Adams where he had a similar rating on DNDN. Pantginis didn't just "pick up" coverage - he merely took the rating he had when he left Cannacord and transfered it over to Merriman. This makes me wonder if Cannacord is even covering DNDN at this time - perhaps a new analyst at Merriman resumed covered after he left. So, Pantginis rating is nothing new, and Huckman should have reported this if he did his due dilgence (instead of crying to get on the nerves of rabbid DNDN fans).

But, facts are facts: Pantginis said CEGE's product was superior due to trial results and stated CEGE would be approved before DNDN's product. He also said CEGE was a buy and recommended this stock to Cannacords institutional investors. Perhaps the following is why Pantginis left Cannacord:

CEGE's stock is now trading at .18 cents because the results of their trial showed they would essentially fail. CEGE is now exploring strategic asset sales of the company (not a good sign the company will remain a viable entity for an extended period of time, IMO). CEGE's business was this one product that they abandoned yesterday.

So, Pantginis is recommending clients buy (as of Friday) a company that now has no product, no future, was trading at $3 recently, and is now trading at .18 cents and is now exploring asset sales of the company, while he says DNDN is a sell, and has an inferior product.

Pantginis is a joke, and Huckman should have done his DD before reporting this.

Licensing Deal Is Imminent for ArQule

This is a good analysis. I'm curious, do you follow that junk ARIA and what are your thoughts there? Thanks